Switch theme
Sign up to access all valuation multiples
APT Medical Inc is engaged in the research and development, production and sales of electrophysiological and vascular interventional medical devices for cardiovascular and cerebrovascular diseases. Its products are sold in Europe, Eastern Europe, Southeast Asia and other countries and other regions.
2002
n/a
LTM Revenue $320M
LTM EBITDA $125M
$5.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
APT Medical has a last 12-month revenue of $320M and a last 12-month EBITDA of $125M.
In the most recent fiscal year, APT Medical achieved revenue of $227M and an EBITDA of $91.6M.
APT Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See APT Medical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $227M | $293M | XXX | XXX | XXX |
| Gross Profit | $79.3M | $119M | XXX | XXX | XXX |
| Gross Margin | 35% | 41% | XXX | XXX | XXX |
| EBITDA | $91.6M | $114M | XXX | XXX | XXX |
| EBITDA Margin | 40% | 39% | XXX | XXX | XXX |
| Net Profit | $28.6M | $49.3M | XXX | XXX | XXX |
| Net Margin | 13% | 17% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, APT Medical's stock price is CNY 432 (or $59).
APT Medical has current market cap of CNY 41.9B (or $5.8B), and EV of CNY 41.0B (or $5.6B).
See APT Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.6B | $5.8B | XXX | XXX | XXX | XXX | $1.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, APT Medical has market cap of $5.8B and EV of $5.6B.
APT Medical's trades at 17.6x LTM EV/Revenue multiple, and 45.1x LTM EBITDA.
Analysts estimate APT Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for APT Medical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.6B | XXX | XXX | XXX |
| EV/Revenue | 19.3x | XXX | XXX | XXX |
| EV/EBITDA | 49.4x | XXX | XXX | XXX |
| P/E | 57.3x | XXX | XXX | XXX |
| P/E/Growth | 1.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAPT Medical's NTM/LTM revenue growth is 32%
APT Medical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, APT Medical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate APT Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for APT Medical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 29% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 71% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 36% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
APT Medical acquired XXX companies to date.
Last acquisition by APT Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . APT Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was APT Medical founded? | APT Medical was founded in 2002. |
| Where is APT Medical headquartered? | APT Medical is headquartered in China. |
| Is APT Medical publicy listed? | Yes, APT Medical is a public company listed on SHG. |
| What is the stock symbol of APT Medical? | APT Medical trades under 688617 ticker. |
| When did APT Medical go public? | APT Medical went public in 2021. |
| Who are competitors of APT Medical? | Similar companies to APT Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of APT Medical? | APT Medical's current market cap is $5.8B |
| What is the current revenue of APT Medical? | APT Medical's last 12-month revenue is $320M. |
| What is the current EBITDA of APT Medical? | APT Medical's last 12-month EBITDA is $125M. |
| What is the current EV/Revenue multiple of APT Medical? | Current revenue multiple of APT Medical is 17.6x. |
| What is the current EV/EBITDA multiple of APT Medical? | Current EBITDA multiple of APT Medical is 45.1x. |
| What is the current revenue growth of APT Medical? | APT Medical revenue growth between 2023 and 2024 was 29%. |
| Is APT Medical profitable? | Yes, APT Medical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
